Intercept pharmaceuticals inc.
Intercept employees are collaborative, passionate and innovative. We strive for excellence every day because we recognize the responsibility of pioneering for patients in need of therapies. Our employees are enthusiastic and hard-working individuals who embody our values of collaboration, integrity, excellence, innovation, passion and patient-centricity. We recognize that developing new ...
MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2023 financial results on Thursday, April 27, 2023, and provide an update on the commercial launch strategy for ...Selected Fourth Quarter and Full Year 2022 Financial Results. Intercept recognized $77.2 million in U.S. net sales in the fourth quarter 2022 as compared to $68.7 million in U.S. net sales in the ...Jul 26, 2023 · MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has resubmitted a New Drug Application (NDA) to the …Intercept Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware. 22-3868459 (State or Other Jurisdiction of. Incorporation or Organization) (I.R.S. Employer. Identification No. ) 305 Madison Avenue, Morristown, NJ. 07960 (Address of Principal Executive Offices and Zip Code) (646) 747-1000
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH ... Learn more about ongoing Intercept-sponsored clinical trials below. Primary biliary cholangitis (PBC) Intercept has two ongoing Phase 2 studies, 747-213 and 747-214, that are designed to explore a range of therapeutic doses for the combination of OCA and bezafibrate. Study 747-213 is for patients outside of the United States. Study 747-214 is for patients … ContinuedContact Email [email protected]. Phone Number +1 646 747 1000. Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with ...
Sep 26, 2023 · Item 1.01 Entry into a Material Definitive Agreement. Agreement and Plan of Merger On September 26, 2023, Intercept Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alfasigma S.p.A. (“Alfasigma”) and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (“Purchaser”).
Selected Fourth Quarter and Full Year 2022 Financial Results. Intercept recognized $77.2 million in U.S. net sales in the fourth quarter 2022 as compared to $68.7 million in U.S. net sales in the ...A biopharmaceutical company, Intercept Pharmaceuticals is developing, and seeking to commercialize, therapies to treat chronic liver disease. Its lead product candidate, obeticholic acid (OCA), is being developed to treat primary biliary cirrhosis, an autoimmune liver disease that can lead to liver failure and death.MORRISTOWN, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept and Advanz Pharma announced on May 5, 2022, has now closed.MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the outcome of the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs ...
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH ...
MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...
Realtime driving directions to Intercept Pharmaceuticals, Inc., 9520 Towne Centre Dr, San Diego, based on live traffic updates and road conditions – from ...Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Save hours of research time and resources with our up-to-date Intercept Pharmaceuticals Inc Strategy Report; Understand Intercept Pharmaceuticals Inc position in the market, performance and strategic initiatives. Gain competitive edge and increase your chances of …MORRISTOWN, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced results from two studies designed to evaluate clinical outcomes in patients with PBC on Ocaliva ...
Glenn Dobbs, Zeke Bratkowski, Tommy Wade, Ken Stabler, Steve DeBerg and Ty Detmer are tied for the NFL record for the most interceptions thrown in one game. Each quarterback has thrown seven interceptions in a single Sunday contest.Dec 20, 2021 · Follow. NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ... Sep 26, 2023 · Item 1.01 Entry into a Material Definitive Agreement. Agreement and Plan of Merger On September 26, 2023, Intercept Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alfasigma S.p.A. (“Alfasigma”) and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (“Purchaser”). Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.MORRISTOWN, N.J., June 07, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced initial results from a planned interim analysis of its ongoing Phase 2 study 747-213 ...Cash on Hand. Long Term Debt. Total Liabilities. Share Holder Equity. Intercept Pharmaceuticals, Inc. total assets from 2013 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet. Intercept Pharmaceuticals, Inc. Annual Total Assets. (Millions of US $)
MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...
Tracfone Wireless Inc has been a leading player in the telecommunications industry, offering innovative solutions and cutting-edge technology to its customers. With a focus on providing reliable and affordable wireless services, Tracfone ha...Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in …EPS. Shares Outstanding. Intercept Pharmaceuticals, Inc. gross profit from 2013 to 2023. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services. Intercept Pharmaceuticals, Inc. Annual Gross Profit. (Millions of US $) 2022 ...Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist ... What is PBC? Primary Biliary Cholangitis (PBC) is a progressive autoimmune disease that damages the bile ducts in the liver. PBC is a leading cause of liver transplant for women. Learn more Ally, living with PBC Patient Resources We are committed to helping patients access disease education, treatment support and financial options. Read moreMar 6, 2023 · March 6, 2023 at 5:59 AM · 17 min read. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) Q4 2022 Earnings Call Transcript March 2, 2023. Operator: Good day and thank you for standing by. Welcome to ... Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Jun 6, 2022 · MORRISTOWN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced an update on the timing of its pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the potential resubmission of its ... Advisory Committee Meeting scheduled for May 19, 2023. PDUFA Target Action Date is June 22, 2023. MORRISTOWN, N.J., March 10, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Gastrointestinal Drugs ...Follow. NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...
১০ আগ, ২০২০ ... “Company” refer, collectively, to Intercept Pharmaceuticals, Inc., a Delaware corporation, and its consolidated subsidiaries. Page 4. ii.
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept ...
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.১০ আগ, ২০২০ ... “Company” refer, collectively, to Intercept Pharmaceuticals, Inc., a Delaware corporation, and its consolidated subsidiaries. Page 4. ii.What is PBC? Primary Biliary Cholangitis (PBC) is a progressive autoimmune disease that damages the bile ducts in the liver. PBC is a leading cause of liver transplant for women. Learn more Ally, living with PBC Patient Resources We are committed to helping patients access disease education, treatment support and financial options. Read moreIntercept Pharmaceuticals, Inc.’s mailing address is 305 Madison Avenue, Morristown NJ 07960, United States. They can be reached by phone at 646 747 1000.Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in …NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...The most common side effects of OCALIVA include: tiredness; stomach pain and discomfort; rash; joint pain; mouth and throat pain; dizziness; constipation; swelling in your hands, ankles, or feet; fast or irregular heartbeat; fever; changes in how your thyroid gland works; dryness, irritation, redness, crusting or drainage of the skin (eczema).Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023.Hayward Pool Products Inc has been a leader in the swimming pool industry for over 90 years. Founded in 1925, Hayward has been committed to providing innovative and high-quality products for residential and commercial pools.To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or ...
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.Intercept Provides Update on NASH Regulatory Timeline. June 6, 2022. PDF Version. MORRISTOWN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver …FXR is a nuclear receptor found in the liver, intestine, kidney, and adipose tissue. FXR regulates many biological processes, including: Bile acid metabolism. Inflammation. Fibrosis. Glucose metabolism. Lipid metabolism. In addition to their role in digestion and absorption, bile acids have been shown to bind and activate dedicated receptors ...Jul 26, 2023 · MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. Instagram:https://instagram. vanguard total international stock etfbest brokerage firm for penny stockshow to invest in nvidiaforex 24 hour trading Following the completion of Alfasigma’s successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash ... tradeweb stockshrimpy business review Nov 8, 2023 · BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma’s ... high risk stocks MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug ...